U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Vaccines, Blood & Biologics
  3. Blood & Blood Products
  4. Approved Blood Products
  5. BeneFIX
  1. Approved Blood Products

BeneFIX

STN: BL 103677
Proper Name:Coagulation Factor IX (Recombinant)
Tradename: BeneFIX
Manufacturer: Wyeth Pharmaceuticals LLC
Indication:

BeneFIX is a recombinant human blood coagulation factor IX indicated for the treatment of:

Adults and children with hemophilia B (congenital factor IX deficiency or Christmas disease) for:

  • On-demand treatment and control of bleeding episodes.
  • Perioperative management of bleeding.

Patients 16 years of age and older with hemophilia B (congenital factor IX deficiency or Christmas disease) for:

  • Routine prophylaxis to reduce the frequency of bleeding episodes.

Limitations of Use

BeneFIX is not indicated for induction of immune tolerance in patients with hemophilia B.

Product Information

Supporting Documents

 

Back to Top